Search - tctmd.com

Displaying 921 - 940 of 1176

Sort: Relevancy | Date

Presentation The Structural Heart Disease Summit 2018

Recent Lessons from the Global Aortic VIVID Registry Optimizing Procedural Outcomes

Presenter: Vinayak Bapat, Ran Kornowski, Danny Dvir

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Cost-effectiveness of Cerebral Protection During TAVR: Can We Justify Systematic Use?

Presenter: Eberhard Grube, Tamim Nazif, Hemal Gada

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Presenter: Eberhard Grube, Tamim Nazif, Chetan P. Huded

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Strokes After TAVR (and SAVR): Incidence in the "Modern Era" and Key Messages From NeuroARC

Presenter: Eberhard Grube, Tamim Nazif, Alexandra J. Lansky

June 21, 2018

Presentation EuroPCR 2018

30-day Outcomes of Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease with Severe Mitral Annular Calcification in the United States: Data from the STS/ACC/TVT Registry

Presenter: Mayra Guerrero

May 24, 2018

Presentation ECHO 2018

Structural Heart Disease-3D echo cases

Presenter: Omar Khalique

April 20, 2018

Update on Mitral Valve Disease and Transcatheter Therapies for Non-Aortic Valves

Presentation Fellows 2018

Cerebral Embolic Protection: A New Standard of Care?

Presenter: Susheel K. Kodali

April 15, 2018

Presentation Fellows 2018

The TAVR Revolution: Past, Present and Future

Presenter: Tamim Nazif

April 15, 2018

Bioskills Session: Focus on Structural Heart Anatomy

Presentation Fellows 2018

Transcatheter Mitral Valve Therapies With a Focus on the MitraClip

Presenter: Susheel Kodali

April 15, 2018

Presentation CIT 2018

Structural Heart Disease: What’s new in 2018?

Presenter: David Hildick-Smith

March 23, 2018

Presentation TCT 2017

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Presenter: Eberhard Grube, James B. Hermiller Jr., Pascal Vranckx

November 01, 2017

Presentation TCT 2017

A Primer of Conduction Abnormalities after TAVR: Frequency, Clinical Consequences, and Revised Management Recommendations (New Permanent Pacemakers)

Presenter: Eberhard Grube, James B. Hermiller Jr., Hemal Gada

November 01, 2017

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

Presentation TCT 2017

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

Presenter: Danny Dvir

November 01, 2017

Presentation TCT 2017

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Presenter: Raj Makkar

November 01, 2017

Presentation TCT 2017

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Presenter: Eberhard Grube, James B. Hermiller Jr., Oluseun Alli

November 01, 2017

Presentation TCT 2017

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Presenter: Eberhard Grube, James B. Hermiller Jr., Megan Coylewright

November 01, 2017

Presentation TCT 2017

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

Presenter: Haim Danenberg

November 01, 2017

Presentation TCT 2017

30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings

Presenter: Mayra Guerrero

November 01, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Advertisement

Recent Lessons from the Global Aortic VIVID Registry Optimizing Procedural Outcomes

Cost-effectiveness of Cerebral Protection During TAVR: Can We Justify Systematic Use?

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Strokes After TAVR (and SAVR): Incidence in the "Modern Era" and Key Messages From NeuroARC

30-day Outcomes of Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease with Severe Mitral Annular Calcification in the United States: Data from the STS/ACC/TVT Registry

Structural Heart Disease-3D echo cases

Cerebral Embolic Protection: A New Standard of Care?

The TAVR Revolution: Past, Present and Future

Transcatheter Mitral Valve Therapies With a Focus on the MitraClip

Structural Heart Disease: What’s new in 2018?

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

A Primer of Conduction Abnormalities after TAVR: Frequency, Clinical Consequences, and Revised Management Recommendations (New Permanent Pacemakers)

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings

Point A Multi-Device Lesion-Specific Approach is Preferred!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content